Literature DB >> 9488037

Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.

L T Amundadottir1, P Leder.   

Abstract

We have assessed five signal transduction pathways to determine the role each might play in the malignant transformation of mammary epithelium initiated by neu, heregulin/NDF, TGFalpha, v-Ha-ras and c-myc in transgenic mice. The study involves a molecular and pharmacologic assessment of Erk/MAP kinase, Jnk/SAP kinase, PI 3-kinase, protein kinase C, and the Src-related kinases Lck and Fyn. Our results indicate that oncogenes capable of transforming mammary gland epithelium activate and require specific signal transduction pathways. For example, mammary tumors initiated by neu, v-Ha-ras and c-myc have high levels of active Erk/MAP kinase and their anchorage independent growth is strongly inhibited by PD098059, an inhibitor of Mek/ MAP kinase kinase. By contrast, Erk/MAP kinase activity is weak in tumors initiated by TFGalpha and heregulin/NDF and the corresponding cell lines are not growth inhibited by PD098059. Similarly, PI 3-kinase is strongly activated in neu, TGFalpha and heregulin/NDF initiated tumor cell lines, but not in c-myc or v-Ha-ras initiated tumor cell lines. The anchorage independent growth of all these tumor cell lines are, however, inhibited by the specific PI 3-kinase inhibitor LY294001. Further illustrating this oncogene-based specificity, PP1, a specific inhibitor of the Src-like kinases, Lck and Fyn, blocks anchorage-independent cell growth only in the TGFalpha initiated mammary tumor cell line. Taken together with additional observations, we conclude that certain oncogenes reliably require the recruitment/activation of specific signal transduction pathways. Such specific relationships between the initiating oncogene and a required pathway may reflect a direct activating effect or the parallel activation of a pathway that is a necessary oncogenic collaborator for transformation in the mammary gland. The work points to a molecular basis for targeting therapy when an initiating oncogene can be implicated; for example, because of amplification, increased expression, genetic alteration, or heritable characteristics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9488037     DOI: 10.1038/sj.onc.1201829

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

Review 1.  Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling.

Authors:  Joyce A Schroeder; Leslie F Jackson; David C Lee; Todd D Camenisch
Journal:  J Mol Med (Berl)       Date:  2003-06-25       Impact factor: 4.599

2.  Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3'-kinase-dependent autocrine loop involving hyaluronic acid and CD44.

Authors:  D M Kamikura; H Khoury; C Maroun; M A Naujokas; M Park
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

3.  Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.

Authors:  R J Lee; C Albanese; M Fu; M D'Amico; B Lin; G Watanabe; G K Haines; P M Siegel; M C Hung; Y Yarden; J M Horowitz; W J Muller; R G Pestell
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  14-3-3ζ loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling.

Authors:  Sonali Joshi; Jun Yang; Qingfei Wang; Ping Li; Hai Wang; Qingling Zhang; Yan Xiong; Brian F Pickering; Jan Parker-Thornburg; Richard R Behringer; Dihua Yu
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

Review 5.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

6.  Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification.

Authors:  Yuzhi Yin; Hongyan Yuan; Xiao Zeng; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

7.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Subhankar Chakraborty; Subhash C Chauhan; Sangeeta Bafna; Jane L Meza; Pankaj K Singh; Michael A Hollingsworth; Parmender P Mehta; Surinder K Batra
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL.

Authors:  Benedetta Accordi; Virginia Espina; Marco Giordan; Amy VanMeter; Gloria Milani; Luisa Galla; Maria Ruzzene; Manuela Sciro; Luca Trentin; Ruggero De Maria; Geertruy te Kronnie; Emanuel Petricoin; Lance Liotta; Giuseppe Basso
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

9.  A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.

Authors:  L E Arias-Romero; O Villamar-Cruz; A Pacheco; R Kosoff; M Huang; S K Muthuswamy; J Chernoff
Journal:  Oncogene       Date:  2010-08-16       Impact factor: 9.867

Review 10.  EGFR may couple moderate alcohol consumption to increased breast cancer risk.

Authors:  Christopher P Mill; Julia A Chester; David J Riese
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.